What it is
Researchers load drugs into nanoparticles that hijack calvarial immune cells, the immune cells resident in the skull, and route them through skull-meninges microchannels directly into the brain, bypassing the blood-brain barrier. The particle-loaded cells are constructed in place by intracalvariosseous (ICO) injection and migrate promptly toward central nervous system lesions when the brain is perturbed. In preclinical stroke models the approach improves both short- and long-term outcomes over conventional delivery, and a prospective clinical trial in patients with malignant stroke supports its translational feasibility.
Why it matters
The blood-brain barrier blocks most systemically delivered drugs from reaching the brain, which is why many central nervous system therapies never reach their target. Routing drug-loaded calvarial immune cells through skull-meninges microchannels reaches lesions without crossing that barrier.
How to read this
It establishes skull-based, immune-assisted transport as a clinically translatable route for delivering drugs to the brain in stroke and potentially other neurological disorders.
Underlined numbers link to their source. See all metrics and figures under Sources below.